Bayer's Innovator In Chief: Kemal Malik
This article was originally published in Scrip
Dr Kemal Malik likes change. The new and novel, which coincidentally is also Malik's definition of innovation, are the momentum that keeps his role as head of innovation at Bayer AG interesting and fun.
You may also be interested in...
Scrip spoke with several executives and attended multiple panel discussions in San Francisco during the first full day of BIO's annual international gathering. Drug pricing and enabling innovation emerged as key themes.
In an exclusive interview, Alexion R&D head John Orloff takes In Vivo on a tour around the company’s rejuvenated pipeline and explains how the business is innovating to pre-empt the Soliris-shaped hole in its balance sheet.
Europe’s patchwork of reimbursement agencies make it a daunting place for a small US biotech to do business. Traditionally large pharma partners or CMSOs have provided an experienced hand to hold, but as a new wave of gene therapies and orphan drugs get the EMA green light, smaller drug developers are applying innovation to commercialization and choosing to go solo.